STYK1 and non-small cell lung carcinoma: To further assess the impact of STYK1 on NSCLC cell sensitivity to EGFR-TKI in vivo, BALB/c nude mice bearing subcutaneous NSCLC xenograft tumors derived from HCC827 cells stably expressing STYK1 shRNA were treated with 25 mg/kg gefitinib.